2nd Quarter - Report

HOLLAND & KNIGHT LLP for ALLIANCE FOR REGENERATIVE MEDICINE

Firm
Client
Income
$80,000
Expenses
—

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Advocate for creation of national strategy for regenerative medicine. Met with OSTP officals regarding same; Advocate for new/modified regulations regarding FDA approval of regenerative medicine products. Spoke with FDA officials about same. Lobbied in support of HR 1862, The Regenerative Medicine Promotion Act of 2011. Lobbied Congress to have provisions inserted in PDUFA reauthorization Energy & Commerce Committee draft legislation. Lobbied for FDA appropriation increase. FDA appropriations eventually included in HR 2112 and S. 2375 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2013. Lobbied for accelerated approval of regenerative medicine products for serious or life threatening conditions. These became part of HR 5651 and FDA Reform Act of 2012 and S. 3187 the FDA Safety and Innoviation Act. Reimbursement policies for regenerative medicine prodcuts; comparative effectiveness research studies related to regenerative medicine products.

LobbyistCovered position, as disclosed
LISA A BARKOVIC —
LINDSAY BRITT —
RANDOLPH FENNINGER New —
PAOLO MASTRANGELO —
MICHAEL WERNER —

Contacted: Natl Institutes of Health (NIH); HOUSE OF REPRESENTATIVES; Agency for Healthcare Research & Quality (AHRQ); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); SENATE; Office of Science & Technology Policy (OSTP)

Bills named: H.R. 2112 (112th), S. 3187 (112th), S. 2375 (112th), H.R. 5651 (112th), H.R. 1862 (112th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.